Milestone Pharma Q3 net loss widens on commercial expenses

Milestone Pharmaceuticals

12/11/2025 12:17

Overview

Milestone Q3 2025 reports no revenue, net loss of $11.9 mln

Company prepares for CARDAMYST launch pending FDA approval in December

Milestone strengthens finances with equity offering and royalty agreement

Outlook

Milestone plans quick launch of CARDAMYST following potential FDA approval

Company expects $75 mln royalty payment upon CARDAMYST FDA approval

Milestone poised to enter Phase 3 program for etripamil in AFib-RVR

Result Drivers

COMMERCIAL EXPENSES - Increased to support pre-launch activities for CARDAMYST nasal spray

FINANCIAL PREPARATION - Equity offering and amended royalty agreement provide resources for CARDAMYST launch

CLINICAL DATA - Etripamil shows consistent efficacy and safety in clinical trials for PSVT

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Basic EPS
-$0.12
Q3 Income From Operations
-$11.83 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Milestone Pharmaceuticals Inc is $4.00, about 52.3% above its November 11 closing price of $1.91

Press Release: ID:nGNX9WQQF4

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)